

2 November 2023

ASX Announcement

Island Pharmaceuticals granted key Australian patent for ISLA-101

- Island's lead asset, ISLA-101 granted key patent from IP Australia covering method of treating or preventing flavivirus infections by administering ISLA-101
- The patent underpins Island's drug repurposing strategy to rapidly and efficiently develop antiviral therapies with a key focus being mosquito borne viral diseases, such as dengue fever
- Around 390 million people are infected with dengue fever each year¹, representing a significant unmet need and opportunity.

MELBOURNE Australia, 2 November 2023: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; "Island"; "the Company") is pleased to announce that a key patent relating to the Company's lead drug candidate, ISLA-101, has been granted by IP Australia.

The Australian patent grant entitled "Method of Viral Inhibition" was issued under Australian Patent No 2021205039 and has an expiration date of 16 April 2034. Claims of the patent are directed to the method of treating or preventing flavivirus infections by administering ISLA-101.

CEO of Island Pharmaceuticals, Dr David Foster said, *"This new patent adds to the growing intellectual property thicket that is being established around ISLA-101. This Australian patent, together with the equivalent patents granted in other key markets, underpin the investment we are making in bringing forward ISLA-101 as a potential new approach to combatting the world's growing problem with dengue fever and other mosquito-borne viral diseases."*

Island has licensed the IP portfolio for ISLA-101, generated by Monash University. This latest Australian patent builds further on a strong IP portfolio that also includes the U.S., Canada, Brazil, and Singapore.

Approved for release to the ASX by:

Dr Paul MacLeman
Executive Chairman
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

¹ <https://www.worldmosquitoprogram.org/sites/default/files/2022-04/WMP%20dengue%20%281%29.pdf>



About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.